Summary Tumours develop through the accumulation of genetic alterations associated with a progressive increase of the malignant phenotype. In lung cancer, chronic exposure of bronchial epithelium to carcinogens in cigarette smoke may lead to multiple dysplastic and hyperplastic lesions scattered throughout the tracheobronchial tree. Little is known about the genetic alterations in such lesions. This study was carried out to examine cyclin Dl (CCND1) and retinoblastoma (RB1) gene expression in the bronchial epithelium of patients with lung cancer. Lung tumours and their corresponding tumour-free resection margins from 33 patients who underwent resection of non-small-cell lung cancer (NSCLC) were examined by immunostaining with monoclonal antibodies against cyclin Dl (DCS-6; Novocastra) and pRb (NCL Rb-1; Novocastra). Examination of the resection margins revealed four carcinomas in situ, 19 hyperplasias and ten sections showing apparently normal bronchial epithelium. A control group of patients, without lung tumours and who had never smoked, revealed no or weak cyclin Dl and positive pRb staining within bronchial epithelia. Increased cyclin Dl and diminished pRb expression were found in 76% (n = 25) and 27% (n = 9) of the resection margins respectively, and in 12% (n = 4) both cyclin Dl and pRb expression were altered. In the corresponding tumours, 48% (n = 16) were normal, while altered expression was found for cyclin Dl in 33% (n = 11), pRb in 27% (n = 9) and both in 9% (n = 3) of cases. It appears that altered expression of cyclin Dl and pRb is an early event in NSCLC development in almost half of cases analysed. Further investigations are needed to determine the significance of immunostaining of bronchial specimens in individuals at risk of lung cancer, with the possibility that the observations are of importance in the early diagnosis of NSCLC.
Lung cancer has become a worldwide problem with a greater than tenfold increase in incidence of reported disease since 1930. Chronic exposure to bronchial irritants appears to lead to epithelial changes, scattered throughout the tracheobronchial tree (Auerbach et al, 1962a (Auerbach et al, ,b, 1975 . Patients with lung cancer have a much greater frequency of epithelial hyperplasia in main bronchi (>90%) compared with patients (10%) who have never smoked (Auerbach et al, 1961) . The best evidence for an association between carcinoma in situ and invasive carcinoma probably comes from sputum cytology from uranium miners, which showed increasingly abnormal epithelial cells as the patients progressed towards invasive lung tumours (Saccomanno et al, 1974) . These results suggest that the whole tracheobronchial tree is affected by carcinogen exposure. Cells with genetic lesions resulting in a growth advantage are likely to replace the epithelium of the whole tracheobronchial tree and, in the case of additional genetic events, may show invasive growth (Thiberville et al, 1995) .
Cyclins, through the targeting of cyclin-dependent kinases (CDKs), control progression of the cell during the various stages of the cell cycle. With respect to cancer, perhaps the most impor-appear to act by phosphorylating and inactivating the retinoblastoma-suppressor protein (pRb). This results in the release, from pRb, of a bound transcription factor E2F. E2F complexes then activate genes necessary for cell division. The p16 protein suppresses the process by competitively binding to the CDK4 molecule. Component genes of this control pathway are frequently mutated, amplified or deleted in malignant cells (for review see Hirama and Koeffler, 1995) . Overexpression of cyclin Dl has been reported in epithelial tumours, such as colorectal, head and neck, oesophageal, breast, uterus, hepatocellular and lung carcinomas, melanomas and sarcomas Bartkova et al, 1994 Bartkova et al, a,b, 1995 Gillett et al, 1994; Nishida et al, 1994; Michalides et al, 1995; Naitoh et al, 1995; Nakagawa et al, 1995) . We have recently reported cyclin Dl overexpression in 43% of non-small-cell lung cancers (NSCLC) (Betticher et al, 1996) . The overexpression was caused by CCNDJ amplification in only 17% of cases. However, in all cases showing overexpression and informative for a HaeIII polymorphism (Heighway, 1991) , an imbalance in allele-specific expression was observed. This suggested specific up-regulation of one CCNDI allele and was consistent with the gene having a key function in lung carcinogenesis.
Cyclin DI and pRb are part of a complicated network that governs cell proliferation. During the last years new proteins (p16, p15, p57, p27 and p2l) were reported to possess inhibitory activity on the cyclin-kinase complexes (Hirama and Koeffler, 1995) . However, since cyclin DI-CDK4-pRb stimulates the proliferation and function before the commitment point, such a deregulation might have primordial importance in malignant growth. We were, therefore, (Betticher et al, 1996) , in two cells lines (SKUT-1-B and MDA-MB-231) known to overexpress cyclin Dl, and in six lung specimens from patients with no lung tumours and who had never smoked. In these patients, lung transplantation was performed because of emphysema (n = 3), interstitial pulmonary fibrosis (n = 2) and bronchiectasis (n = 1).
Immunohistochemistry
The immunohistochemistry was performed as described previously (Gillett et al, 1994; Geradts et al, 1994; Betticher et al, CCND1 and RB1 is NSCLC and (pRb-) (breast cancer, resection margins with respective NSCLC) and lung specimens were air dried on 2% APTS (Sigma, Poole, UK) coated slides. After dewaxing in xylene, the sections were treated for 15 min with 300 ml of methanol and 10 ml of hydrogen peroxide to block endogenous peroxidase and rinsed thoroughly in water. They were then placed in citrate buffer, boiled twice in a microwave, washed with water and placed in Tris buffer (pH 7.6). After incubation in 1:100 goat serum for 20 min at room temperature, they were placed either in 1% bovine serum albumin (BSA) and 1:100 mouse monoclonal cyclin Dl antibody (DCS-6; Novocastra, Newcastle, UK) or in 1% BSA and 1:50 mouse monoclonal pRb antibody (NCL-Rbl; Novocastra) overnight at room temperature. After two washes with Tris buffer, they were incubated in 1:100 biotinylated goat anti-mouse/rabbit IG (Dako, British Journal of Cancer (1997) Glostrup, Denmark) for 30 min, washed twice with Tris, incubated in a 1:100 solution of streptavidin biotin complex for 30 min at room temperature, rewashed in Tris buffer and placed in diaminobenzedine (10 mg 10 ml-1) for 10 min, counterstained with haematoxylin, washed in water, cleared, dehydrated and mounted. Cyclin DI and pRb staining was examined according to the intensity of the majority of cells. The slides were assessed blind in two series; thus, the pathologist did not know the results of cyclin DI expression when examining the pRb staining. Positive and negative control experiments were performed for each tumour series. For cyclin DI, two categories of staining were used: nil-weak (negative) and moderate-strong (positive). For pRb, specimens were considered negative when control cells (lymphocytes and endothelial cells) were positive, but nuclei of tumour or epithelial cells in the resection margins showed no staining.
Statistical analyses
Patients were placed into two groups according to their cyclin DI/pRb expression, e.g. normal: pRb+, cyclin Dl-v pRb-and/or cyclin D1+. Associations of group membership with other patient and tumour characteristics were made with chi-square tests for categorical features and Mann-Whitney U-tests for continuous ones. Kaplan-Meier survivor function estimates were used and simple comparisons between the two groups were made with the log-rank test.
RESULTS

NSCLC and resection margins
Thirty-three patients with operable NSCLC were examined for epithelial precancerous lesions in their respective resection margins. According to the WHO classification (1981), the histological subtypes were as follows: 26 squamous carcinomas, five adenocarcinomas, one large-cell carcinoma and one bronchial carcinoid. The resection margin specimens free from tumour showed carcinoma in situ in four, epithelial hyperplasia or dysplasia in 19 and apparently normal epithelium in ten cases. Interestingly, patients below 60 years (P = 0.01) and with poor tumour differentiation (P = 0.06) appeared to be associated with a Figure 1A) .
In lungs of patients with NSCLC, the epithelial cells in the resection margins were positive in 25 cases (76%) ( Table 3 and Figure iB). In general, dysplastic cells revealed strong positivity, while hyperplasia had more frequent moderate positivity. In some cases, strong positivity was also found in epithelial cells of apparently normal epithelium. In all cases, cyclin Dl was localized to the cytoplasm, while concurrent nuclear staining was seen in five of 25 positive cases. In the tumours, 11 (33%) were positive and 22 specimens (66%) showed no or little staining comparable with the pattern seen in normal tissue. Cytoplasmic cyclin Dl localization was seen in all tumours and additional nuclear staining in 8/11 of cases ( Figure IC) . The frequency of tumours staining in this independent series (patients from UK) is similar to that reported in our earlier (Swiss patients) study (Betticher et al, 1996) . Inflammatory and endothelial cells, and fibroblasts were uniformly negative. Serous glands showed strong cytoplasmic positivity for cyclin D1 staining.
Retinoblastoma protein expression
Expression of the pRb protein in tumours was assessed using a mouse monoclonal pRb antibody that has been reported to bind to the pRb protein independently of the phosphorylation status and the presence of certain point mutations (Bartek et al, 1992) . The immunostaining of the non-cancerous lung tissue showed typical staining patterns. In particular, the pRb protein was present in the nuclei of some, but not all, bronchial epithelial cells, stromal cells (especially lymphocytes and endothelial cells) and bronchial glandular and ductal cells. The examination of epithelial cells in the resection margin revealed the presence of the pRb protein in 24/33 specimens. No staining was seen in nine resection margins (27%). In the tumour, 17 (52%) were strongly positive for pRb staining, seven (21%) were moderately positive and nine tumours (27%), including two cases with aberrant pRb expression in the resection margin, were negative for pRb expression (Table 3 and Figure  lD -E). Nuclear pRb subcellular localization was observed in all cases, although weak concomitant cytoplasmic staining was seen in some specimens.
Taken together, in the normal control tissues, low cyclin Dl expression and pRb nuclear staining was seen. Conversely, altered expression was found in 30 epithelia of resection margins (91%) and in 17 NSCLC (52%) ( Table 3 ). In view of the presumed nuclear cyclin D1-pRb interaction, the analysis was made for cyclin Dl nuclear staining only; 14 resection margins (42%) and 15 tumours (46%) revealed altered expression (Table 3) . No resection margin and only two tumours had simultaneous nuclear CCNDJ and RBI deregulation.
Cyclin D1/RB1 staining in correlation with pathology and clinical outcome We found no obvious correlation between cyclin DI and/or pRb protein expression and specific pathological parameters of the NSCLC examined. The overall survival (Figure 2 ) tends to correlate with cyclin DI and/or pRb deregulation in the tumour; the median survival of patients with normal cyclin D 1 and pRb protein expression was 3.5 years compared with 1.3 years when cyclin Dl and/or the pRb protein was abnormal (P = 0.20).
DISCUSSION
Acquisition of a malignant phenotype follows the accumulation of multiple genetic changes by a cell. These may include deletions, point mutations, chromosomal translocations or gene amplifications. Support for this view is found in colon carcinoma is which a typical sequence of genetic changes has been described (Vogelstein et al, 1988) . In NSCLC, it is reasonable to assume that the bronchial epithelium is progressively damaged by chronic carcinogen exposure. In this study, 23/33 epithelia showed histological alterations, including hyperplasia and carcinoma in situ, British Journal of Cancer (1997) 75(12) and interestingly, these changes were associated with low age and poor tumour differentiation.
Mutation of KRAS2 seems to be an early event in a third of lung adenocarcinomas (Rodenhuis et al, 1987) . Other genetic lesions have been reported in NSCLC, such as interference with RBI (Xu et al, 1991; Reissmann et al, 1993; Higashiyama et al, 1994; Geradts et al, 1994; Xu, 1995) compared with normal tissues (Cordon-Cardo and Richon, 1994) and TP53 gene (Chiba et al, 1990 ) mutations, as well as overexpression of the ERB-B2 (Carbone and Minna, 1992) and CCNDI (Schauer et al, 1994; Shapiro et al, 1995; Betticher et al, 1996) genes. However, little is known about their presence in precancerous lesions and their significance in tumorigenesis. Overexpression of cyclin DI at early stages of tumour development has been reported recently in several studies on premalignant skin lesions in mice (Robles and Conti, 1995) , in human carcinoma in situ of the breast (WeinstatSaslow et al, 1995) , in familial adenomatous polyposis of the colon , in premalignant epithelia of patients with head and neck tumours (Izzo et al, 1996) or gastric and oesophageal cancer (Arber et al, 1996) . In mice, cyclin Dl was found to be overexpressed in precancerous lesions, including small incipient papillomas, after induction by a two-stage carcinogenesis protocol (Robles and Conti, 1995) . Normal and hyperproliferative skin were negative for cyclin Dl, and the intensity of cyclin D1 staining was associated with the grade of dysplasia. Another study (Weinstat-Saslow et al, 1995) reports on a large number of human breast biopsies, in which cyclin DI overexpression was found in 87% of ductal carcinoma in situ and in 83% of invasive breast carcinoma lesions, but rarely in normal tissue.
During the multistep evolution of cancers, the normal inhibitory role of pRb in the cell cycle progression can be abrogated by various mechanisms, including increased levels of cyclin Dl, direct loss of pRb function or other mechanisms, not yet identified, that might override pRb. According to this model and at the simplest level, there might be little selective advantage in the coincident occurrence within a tumour cell of up-regulation of the cyclin Dl gene and loss of Rb function. Indeed, a strong association between altered cyclin Dl and pRb expression has been reported in oesophageal tumours . Tumours and cell lines that had CCNDI amplification and cyclin Dl overexpression exhibited normal levels of expression of pRb. In contrast, tumours and cell lines that did not appear to express the pRb did not show CCNDI amplification and expressed only low levels of cyclin Dl. Similarly, in lung cancer, SCLC cell lines with low or undetectable cyclin Dl expression had no pRb staining. In contrast, in all NSCLC cell lines studied, cyclin Dl was overexpressed, while the expression of the pRb protein appeared normal (Schauer et al, 1994) .
In this study on primary NSCLC tumour specimens, such a strong association was not found. Of the 17 tumours showing abnormal cyclin Dl or pRb expression, three showed apparent overexpression of CCNDI and no detectable RBI expression, while 14 showed abnormal expression of one or other gene. However, it is perhaps worth noting that positive staining for pRb does not necessarily reflect a functional retinoblastoma protein. Indeed, the antibody used binds to pRb independently of the presence of some point mutations (Bartek et al, 1992) . Considering the resection margins, the majority (21/33, including 8/10 histologically normal epithelia) showed normal pRb but elevated cyclin Dl levels. Cells in four margins demonstrated aberrant expression of both genes (Table 3) . But most interestingly, epithelial cells from only three margins showed apparently normal levels of both proteins. One explanation for the observation that CCNDI and RBI expression is perturbed in epithelial cells from the tumourfree margins is that alterations of these key cell cycle control genes can occur at a very early stage in the development of lung cancer.
Consistent with our earlier study of resectable NSCLC (Betticher et al, 1996) , in the majority of tumours analysed, the cyclin DI protein detected in the sections was predominantly cytoplasmic. This pattern was also the predominant mode of staining in cells from the resection margins. Cytoplasmic staining has been reported in a number of other malignant tissues (Gillett et al, 1994; Nakamura et al, 1994; Banno et al, 1994; Zhang et al, 1994; Swerdlow et al, 1995; Kuroda et al, 1995) . It has been suggested that this pattern might be artifactual with only nuclear staining reflecting true overexpression of CCNDJ. While this possibility cannot be completely ruled out, we feel it is insufficient to explain the data; Our initial study (Betticher et al, 1996) combined an analysis of CCNDJ amplification, immunohistochemistry and a determination of allele-specific expression levels. The predominant mode of staining in NSCLC cells was cytoplasmic. In all cases in which elevated protein levels were observed, an imbalance in allele-specific mRNA levels was seen. A control series of breast tumours was also analysed, and in these samples the predominant mode of staining was, as expected, nuclear. We therefore feel that the cytoplasmic staining observed reflects elevated levels of cyclin DI within the cells. Furthermore, immunhistochemistry of cell lines (SKUT-l-B and MDA-MB-231) known to overexpress cyclin Dl at the RNA and protein levels (Kurzrock et al, 1995) revealed strong, exclusively cytoplasmic, staining.
This raises questions as to why the cyclin Dl protein should be localized in the cytoplasm, if its main role in promoting growth is to phosphorylate pRb, thereby facilitating cell cycle progression? Alternate splicing of the CCNDI gene has been reported (Betticher et al, 1995) . It is not inconceivable that alternate cyclin Dl proteins produced from such transcripts might have distinct function and subcellular localizations and yet still be recognized by DCS-6.
Strong cytoplasmic cyclin Dl staining was also present in a great number of serous glands. Bronchial glands proliferate in response to chronic damage of the tracheobronchial epithelium. Since glandular as well as basal cells are able to differentiate into adult epithelium, it has been hypothesized that any cell capable of division has the potential to produce hyperplastic, metaplastic and neoplastic lesions composed of cells that may differ phenotypically from the parent cell(s) (McDowell and Beals, 1986) . However, the exact significance of glandular tissue in carcinogenesis and, in particular, the implication of cytoplasmic cyclin Dl overexpression in these cells and resection margins remain to be established.
Taken together, normal cyclin DI and pRb expression was found in only three resection margin epithelia in which the corresponding tumours also showed no pathological expression of these genes. In six resection margins, identical abnormal expression patterns were seen as in the corresponding tumour (Table 3) . Finally, three resection margin specimens with cyclin Dl overexpression had additionally altered pRb expression in their tumour. In contrast, the finding that 13 bronchial epithelia with abnormal expression (cyclin Dl overexpression or pRb negativity) had normal immunostaining in their tumours, while at first sight appearing perplexing, might in fact be explained by the evolutionary history of the patients' condition. CCND1 and RB1 is NSCLC and resection margins 1767 Kishimoto et al (1995) have reported loss of heterozygosity (LOH) for 9p (the location of a third G1 control gene CDKN2, which encodes p16) in preneoplastic NSCLC lesions. Surprisingly, when multiple, geographically and morphologically distinct lesions were examined, LOH for the same 9p allele was reported. There are several possible explanations for these results, including the preferential loss of one parental region of 9p, in the development of malignant disease. However, as discussed by Sidransky (1995) , this result might reflect an initial lesion in just one cell in these patients. As these cells proliferate, they become geographically disseminated. Subsequent genetic changes in the separated lesions of this clonal population would then occur independently, perhaps leading to histologically distinct preneoplastic areas. Such a model of clonal evolution may help to explain our results. At least in the cases in which the tumours and margins give different pathological staining patterns for cyclin Dl and pRb, we would have to conclude that alteration of these genes, although perhaps an early event in the development of the disease, was not the primary neoplastic lesion but was linked to further tumour development. We would therefore hypothesize an initial lesion in a target cell, which underwent a clonal expansion within the organ. Subsequent mutational events would push progeny of this cell down pathways towards full malignant transformation. However, these events after the initial lesion would be independent. Unless we analyse the primary alteration, subsequent investigation could show that different epithelial areas (including the resultant tumour) would possess different genetic alterations.
A second and perhaps a more simple explanation might be that the tumour and abnormal margin epithelia represent completely independent initiation events. In this hypothesis, the patient's lung might contain numerous independent early lesions, as a consequence of chronic and repeated exposure to the carcinogens present in cigarette smoke. If we think of multiple, preneoplastic epithelial areas scattered throughout the organ, then the data could be interpreted to suggest that lesions with overexpression of cyclin Dl are less likely to progress to full malignancy. This surprising idea arose in part from the consideration of four separate studies, in which overexpression of CCNDI in tumours appeared to be associated with a less aggressive phenotype or was a favourable prognostic indicator (Betticher et al, 1996; Bringuier et al, 1996; Gillett et al, 1996; Pelosio et al, 1996) .
In conclusion, it would appear that aberrant expression of cyclin Dl and pRb, potentially resulting in the loss of control of cell cycle progression, could be early events in the development of NSCLC. Further molecular investigations into the mechanisms resulting in these alterations of gene expression in preneoplastic lesions are warranted to define the significance of cyclin Dl and pRb immunostaining of epithelial specimens obtained by bronchoscopy, with the possibility that this finding is of importance in the early diagnosis of NSCLC.
